Rxsight Inc (RXST) - Total Liabilities
Based on the latest financial reports, Rxsight Inc (RXST) has total liabilities worth $36.70 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rxsight Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Rxsight Inc's total liabilities have evolved over time, based on quarterly financial data. See Rxsight Inc (RXST) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Rxsight Inc Competitors by Total Liabilities
The table below lists competitors of Rxsight Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Circio Holding ASA
OL:CRNA
|
Norway | Nkr23.25 Million |
|
Astec LifeSciences Limited
NSE:ASTEC
|
India | Rs4.69 Billion |
|
Legal & General Group PLC
LSE:LGEN
|
UK | GBX579.96 Billion |
|
BIDV Insurance Corp
VN:BIC
|
Vietnam | ₫6.70 Trillion |
|
Amotech Co. Ltd
KQ:052710
|
Korea | ₩175.85 Billion |
|
PTT Synergy Group Bhd
KLSE:7010
|
Malaysia | RM1.39 Billion |
|
Thanulux Public Company Limited
BK:TNL
|
Thailand | ฿4.77 Billion |
|
Amway (Malaysia) Holdings Bhd
KLSE:6351
|
Malaysia | RM246.59 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Rxsight Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Rxsight Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rxsight Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rxsight Inc (2019–2025)
The table below shows the annual total liabilities of Rxsight Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $36.13 Million | -3.20% |
| 2024-12-31 | $37.33 Million | +68.22% |
| 2023-12-31 | $22.19 Million | -63.18% |
| 2022-12-31 | $60.26 Million | +10.62% |
| 2021-12-31 | $54.48 Million | -86.32% |
| 2020-12-31 | $398.21 Million | -4.06% |
| 2019-12-31 | $415.04 Million | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more